Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE) -- Ignore unavailable to you. Want to Upgrade?

To: burner who wrote (144)	1/25/1998 9:25:00 AM
From: trustmanic	Read Replies (1) \| Respond to of 193

Dan, I did a little reseach, Helix is a better play in the future. This time the management was right, they needed to refocus on their DNA business rather than doing so many things. Helix could make money and Helix's position was better than most small biotechs while their research still a long way to go. I don't have much hope for RRK, and I'll concentrate on a few biotech this year. Novadx launched their first product Chondrex this month, and Metra just announced that they bought 2 millions of NVN at 0.3055. The share price should improved after they announce the pharmaceutical deal this Q. I'll buy more HBP when I get my tax refund.BTW, they mentioned that they needed financing, what for? Are they still in generic drugs? Regards Dan